Jan 12 () - Merck said on Monday it ​has raised its ‌outlook for new growth drivers, ‌forecasting $70 billion in revenue from ...
The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback